FDA Approves Gene Modification To Fight Cancer

Novartis AG have finally gotten the go-ahead from the U.S. Food and Drug Administration to proceed with a gene-modifying immunotherapy that will battle leukemia, but also opens the doors to tackling other types of cancer down the line, as well.

The major downside, though, is it costs $475,000 -- which means unless you're rich or want your future generations to be paying off the bill for this, it may be out of reach.

Doctors do, however, agree that the price point is insanely high, as one New York doctor made it sound like if he can save a life, regardless of the price, he may just do it anyway.

Of course, we have to talk about pricing from a national standpoint, but if I have a parent and a (sick) child in front of me, and I have an opportunity to save them, we’re going to take that.

 
Jadd

Jadd

Want to know more about Jadd? Get their official bio, social pages & articles! Read more

title

Content Goes Here